Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the lot consistency, immunogenicity and safety of three lots of Sabin strain inactivated polio vaccine (Vero Cell) (sIPV) manufactured at commercial scale by Sinovac Biotech Co., Ltd., and evaluate the non-inferiority of investigational vaccine against a post-market inactivated polio vaccine.

Clinical Trial Description

This study is a randomized, double-blinded, and positive-controlled clinical trial. A total of 1300 infants aged 2 months will be enrolled and assigned to 4 groups in a ratio of 1:1:1:1 to receive vaccination of 3 lots of investigational sIPV and control IPV manufactured by Sanofi Pasteur S.A respectively. Each subjects should finish the three-doses primary vaccination at the schedule of 2,3,4 months of age. Thirty-days safety observation after each dose of vaccination will be carried out. Venous blood should be collected from all the subjects before and 30 days after the three-doses primary vaccination, for the neutralizing antibody assay, and further to evaluate the immunogenicity. ;

Study Design

Related Conditions & MeSH terms

Poliomyelitis

Clinical Trial Details

NCT number	NCT04386707
Study type	Interventional
Source	Sinovac Biotech Co., Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	May 11, 2020
Completion date	October 20, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04989231` - An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
Completed	`NCT00352963` - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).	Phase 3
Recruiting	`NCT03890497` - Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh	Phase 4
Completed	`NCT00753649` - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants	Phase 4
Completed	`NCT04693286` - Clinical Trial of Novel OPV2 Vaccine	Phase 2
Completed	`NCT02847026` - Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study	Phase 4
Completed	`NCT02189811` - Polio End-game Strategies - Poliovirus Type 2 Challenge Study	Phase 4
Completed	`NCT01444781` - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants	Phase 3
Completed	`NCT01214889` - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.	Phase 3
Completed	`NCT00879827` - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants	Phase 3
Completed	`NCT01457495` - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly	Phase 2
Completed	`NCT02853929` - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Phase 4
Completed	`NCT03614702` - Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV	Phase 3
Terminated	`NCT04063150` - Immunogenicity of Intramuscular and Intradermal IPV	Phase 4
Completed	`NCT04614597` - A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
Completed	`NCT03239496` - A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV	Phase 3
Completed	`NCT04544787` - A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates	Phase 2
Completed	`NCT02985320` - Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine	Phase 1/Phase 2
Completed	`NCT02274285` - DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants	Phase 3
Completed	`NCT02291263` - Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine	Phase 3